Binding molecules capable of neutralizing rabies virus and uses thereof
Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
1. A pharmaceutical composition comprising at least two rabies virus neutralizing monoclonal antibodies or antigen-binding fragments thereof, that are capable of reacting with different, non-competing epitopes of the rabies virus, wherein a first rabies virus neutralizing monoclonal antibody or antigen-binding fragment thereof, is capable of reacting with an epitope located in antigenic site I wherein the epitope comprises amino acids 226-231 of the rabies virus G protein and a second rabies virus neutralizing monoclonal antibody, or antigen-binding fragment thereof, is capable of reacting with an epitope located in antigenic site III of the rabies virus G protein.
2. A pharmaceutical composition comprising two rabies virus neutralizing binding molecules that are capable of binding to different, non-competing epitopes of the rabies virus, the composition comprising:
a first rabies virus neutralizing binding molecule capable of binding to an epitope located in antigenic site I of the rabies virus G protein, said first rabies virus neutralizing antibody comprising:
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 273 or a sequence that is at least 80% homologous thereto, and
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 275 or a sequence that is at least 80% homologous thereto, and
a second rabies virus neutralizing binding molecule capable of binding to an epitope located in antigenic site III of the rabies virus G protein.
3. The pharmaceutical composition of claim 2 , wherein the second rabies virus neutralizing binding molecule comprises:
i) a heavy chain variable region comprising SEQ ID NO: 29 and a light chain variable region comprising SEQ ID NO: 53; or
ii) a heavy chain variable region comprising SEQ ID NO: 35 and a light chain variable region comprising SEQ ID NO: 59; or
iii) a heavy chain variable region comprising SEQ ID NO: 39 and a light chain variable region comprising SEQ ID NO: 63; or
iv) a heavy chain variable region comprising SEQ ID NO: 40 and a light chain variable region comprising SEQ ID NO: 64; or
v) a heavy chain variable region comprising SEQ ID NO: 41 and a light chain variable region comprising SEQ ID NO: 65; or
vi) a heavy chain variable region comprising SEQ ID NO: 47 and a light chain variable region comprising SEQ ID NO: 71.
4. The pharmaceutical composition of claim 2 , wherein the first rabies virus binding molecule is an IgG and the second rabies virus binding molecule is an IgG.
5. A pharmaceutical composition comprising at least two rabies virus neutralizing monoclonal antibodies, or antigen-binding fragments thereof, that are able to react with different, non-competing epitopes of rabies virus, wherein
a first rabies virus neutralizing monoclonal antibody or antigen-binding fragment thereof, is able to react with an epitope located in antigenic site I and comprising amino acids 226-231 of the rabies virus G protein, and
a second rabies virus neutralizing monoclonal antibody or antigen-binding fragment thereof, is able to react with an epitope located in antigenic site III of the rabies virus G protein, wherein said rabies virus neutralizing antibodies are human antibodies.